We are excited to share our editorial that was published recently in the Journal of the American College of Cardiology (JACC), where we explored key findings from the AEGIS-II trial.
The AEGIS-II trial was a large-scale, Phase III cardiovascular outcomes study investigating CSL112, a plasma-derived human apolipoprotein A-I therapy, aimed at enhancing reverse cholesterol transport and plaque remodeling in patients with multi-vessel coronary artery disease who had suffered a Type 1 myocardial infarction (MI).
While the primary results of the AEGIS-II trial were neutral, our exploratory analyses highlight the need for more nuanced MI definitions in clinical trials. We believe this research is a step forward in understanding how therapies like CSL112 might impact different MI subtypes and in advancing the way we design future cardiovascular trials.
Read more about our editorial comment here: Exploring the Need for Precise MI Adjudication in Clinical Trials - PubMed (nih.gov)